A simulation model for colorectal cancer screening: Potential of stool tests with various performance characteristics compared with screening colonoscopy

Cancer Epidemiology Biomarkers and Prevention

Volumn 14, Issue 2, 2005, Pages 422-428

  Haug, Ulrike ^a   Brenner, Hermann ^a  

^a German Centre for Research on Aging   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER PREVENTION; CANCER SCREENING; COLONOSCOPY; COLORECTAL CANCER; COMPARATIVE STUDY; EARLY DIAGNOSIS; FECES ANALYSIS; FOLLOW UP; HUMAN; MASS SCREENING; PERFORMANCE; PRECANCER; PRIORITY JOURNAL; PROBABILITY; RISK REDUCTION; SENSITIVITY AND SPECIFICITY; SIMULATION; TUMOR CELL;

AGED; COLONOSCOPY; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; MARKOV CHAINS; MASS SCREENING; MIDDLE AGED; OCCULT BLOOD; SENSITIVITY AND SPECIFICITY;

EID: 13944265977     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-04-0411     Document Type: Article

References (25)

1. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2000: Cancer Incidence, Mortality and Prevalence Worldwide, Version 1.0. IARC CancerBase Nol 5. Lyon: IARC, 2001 http://www-dep.iarc.fr/globocan/globocan.html.
2. Atkin WS, Northover JM. Protagonist: population based endoscopic screening for colorectal cancer. Gut 2003;52:321-2.
3. Macafee DA, Scholefield JH. Antagonist: population based endoscopic screening for colorectal cancer. Gut 2003;52:323-6.
4. Pignone M, Saha S, Hoerger T, Mandelblatt J. Cost-effectiveness analyses of colorectal cancer screening: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2002;137:96-104.
5. Ahlquist D. Stool-based DNA tests for colorectal cancer: clinical potential and early results. Rev Gastroenterol Disord 2002;w2:20-6.
6. Davies RJ, Freeman A, Lesley SM, Bingham S, Dilworth S, Coleman N. Analysis of minichromosome maintenance proteins as a novel method for detection of colorectal cancer in stool. Lancet 2002;359:1917-9.
7. Mizuno M, Mizuno M, Iwagaki N, et al. Testing of multiple samples increases the sensitivity of stool decay-accelerating factor test for the detection of colorectal cancer. Am J Gastroenterol 2003;98:2550-5.
8. Yamao T, Matsumura Y, Shimada Y, Moriya Y, Sugihara K, Akasu T. Abnormal expression of CD44 variants in the exfoliated cells in the feces of patients with colorectal cancer. Gastroenterology 1998;114:1196-205.
9. Tibble J, Sigthorsson G, Foster R, Sherwood R, Fagerhol M, Bjarnason I. Faecal calprotectin and faecal occult blood tests in the diagnosis of colorectal carcinoma and adenoma. Gut 2001;49:402-8.
10. Lang CA, Ransohoff DF. Fecal occult blood screening for colorectal cancer. Is mortality reduced by chance selection for screening colonoscopy? JAMA 1994;271:1011-3.
11. Hardcastle JD, Chamberlain JO, Robinson MH, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996;348:1472-7.
12. http://www.cancer.org/docroot/PED/content/PED_2_3X_ACS_Cancer_- Detection_Guidelines_36.asp?sitearea=PEDwww.cancer.org/docroot/PED/content/ PED_2_3X_ACS_Cancer_Detection_Guidelines_36.asp? sitearea=PED, accessed July 30th 2004.
13. U.S. Preventive Services Task Force. Screening for colorectal cancer: recommendations and rationale. Ann Intern Med 2002;137:129-31.
14. Winawer S, Fletcher R, Rex D, et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale update based on new evidence. Gastroenterology 2003;124:544-60.
15. www.krebsregister.saarland.de, accessed July 24th 2003.
16. Brenner H, Arndt V, Stürmer T, Stegmaier C, Ziegler H, Dhom G. Long-lasting reduction of risk of colorectal cancer following screening endoscopy. Br J Cancer 2001;85:972-6.
17. Newcomb PA, Storer BE, Morimoto LM, Templeton A, Potter JD. Long-term efficacy of sigmoidoscopy in the reduction of colorectal cancer incidence. J Natl Cancer Inst 2003;95:622-5.
18. Allison JE, Tekawa IS, Ransom LJ, Adrain AL. A comparison of fecal occult blood tests for colorectal-cancer screening. N Engl J Med 1996;334:155-9.
19. Ederer F, Church TR, Mandel JS. Fecal occult blood screening in the Minnesota study: role of chance detection of lesions. J Natl Cancer Inst 1997;89:1423-8.
20. Birkner B. Strategies for colorectal cancer screening. J Cancer Res Clin Oncol 2004;130:S4.
21. Vernon SW. Participation in colorectal cancer screening: a review. J Natl Cancer Inst 2003;89:1406-22.
22. Song K, Fendrick AM, Ladabaum U. Fecal DNA testing compared with conventional colorectal cancer screening methods: a decision analysis. Gastroenterology 2004;126:1270-79.
23. Plazier AL, Colditz GA, Fuchs CS, Kuntz KM. Cost-effectiveness of screening for colorectal cancer in the general population. JAMA 2000;284: 1954-61.
24. Jartz NK, Wren PA, Schottenfeld D, Guire KE. Colorectal cancer screening attitudes and behavior: a population-based study. Prev Med 2003;37: 627-34.
25. Schoen RE, Weissfeld JL, Trauth JM, Ling BS, Hayran M. A population-based, community estimate of total colon examination: the impact on compliance with screening for colorectal cancer. Am J Gastroenterol 2002;97:446-51.